Ophthalmology

A team of clinicians and investigators are working to define core outcome sets that it hopes will increase the utility of randomized clinical trials and stimulate research.

The 24-2 visual field test was comparably worse than other tests in consideration to glaucoma patients' central vision.

Anti-VEGF injection therapy is the proven choice of care for AMD and DME. Still, concerns about dosing, costs, and convenience persist into 2019.

After successful trials in animal models, researchers say they will soon launch clinical trials of an eye drop to treat age-related macular degeneration.

A new imaging technique may provide improvements to the diagnosis and treatment of diseases like age-related macular degeneration (AMD).

A new study finds high-dose intravitreal triamcinolone acetonide is a safe alternative to anti-vascular endothelial growth factor, a finding that is welcome news for patients in low-income countries.

Patients with diabetic macular edema who do not show sufficient progress after anti-VEGF-A treatment may soon have a new option.

Ophthotech says it’s sidelining its Zimura/Lucentis program despite positive phase 2a results.

The FDA has approved Dextenza, a dexamethasone ophthalmic insert, for the treatment of ocular pain following ophthalmic surgery.

The effects of Charles Bonnet Syndrome have been fairly documented, yet its pathology has been minimally assessed.

Traditional therapy includes anti-VEGF injections into the eye. This is effective in many patients, but some remain unresponsive. Recent studies have suggested this new target.

A new review of literature about 2 anti-VEGF therapies for diabetic macular edema suggest the drugs hold promise, but not without some caveats.

Combining glaucoma medications into a single eye drop could simplify regimens and reduce costs for patients. Investigators found that a combination eye drop also significantly reduced intraocular pressure compared to control.

Patients with diabetic macular edema (DME) switching to aflibercept from ranibizumab improved their BCDA by an average of 5 letters over 9-12 months.

Authors compared investigator assessments to reading center-assessed optical coherence tomography outcomes to evaluate intravitreal aflibercept injection with or without rescue photodynamic therapy.

A new study emphasizes the need for specially designed syringes that ensure accuracy and precision when administering anti-VEGF agents via intravitreal injection.

Ronald Gentile, MD, and colleagues investigated pain-reduction strategies following intravitreal injections. The results have implications for patient experience, physician ratings, and treatment adherence.

R. Theodore Smith, MD, PhD, discusses the importance of developing non-invasive technologies that can detect age-related macular degeneration earlier.

A new phase 3 study suggests that physicians should shift away from periocular injections, and towards intravitreal injections of corticosteroids for uveitic macular edema.

While it is critical to recognize diabetic macular edema patients with delayed treatment response to reduce the progression of vision loss, improve quality of life, this may come at a cost to the institution.

After analyzing 57,925 injections administered 2013 and 2017, investigators observed an increase in aflibercept use, with a reciprocal decline in ranibizumab across all regions, while the use of bevacizumab remained stable.

Patients treated with faricimab every 16 weeks had a mean improvement of 11.4 letters from baseline, compared to 9.6 letters in those treated with ranibizumab every 4 weeks.

The phase 2 FILLY trial found that APL-2 injections both monthly and every other month slowed lesion growth compared to sham.

The data presented at the American Academy of Ophthalmology indicates dosing IAI with treat and extend resulted in more visual acuity gains when compared to fixed dosing.

According to an analysis of 84,228 online reviews of 7,372 ophthalmologists, the average rating for a physician with a wait time exceeding 15 minutes was 3.903.

In a new study conducted in Taiwan, investigators found that use of metformin to treat diabetes also reduced the risk of AMD development over a 13-year period.

In patients with neovascular AMD, 24% receiving brolucizumab had intra-retinal fluid and/or sub-retinal fluid compared to 37% of aflibercept-treated patients in the HAWK trial.

Peter Campochiaro, MD, professor of ophthalmology and director of the retinal cell and molecular laboratory at Johns Hopkins explains the burdens of receiving frequent anti-VEGF injection treatments.

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy and diabetic macular edema.

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months was 1.3 in a phase 1 cohort study.